{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:32:37Z","timestamp":1792071157334,"version":"4.4.0"},"reference-count":190,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.011","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T13:30:37Z","timestamp":1364304637000},"page":"885-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis"],"prefix":"10.1016","volume":"12","author":[{"given":"Sonia","family":"Berrih-Aknin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Ragheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozen","family":"Le Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Lisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.03.011_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2006.00606.x","article-title":"Clinical aspects of neuromuscular transmission disorders","volume":"183","author":"Evoli","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.autrev.2013.03.011_bb0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/286738a0","article-title":"Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia","volume":"286","author":"Richman","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.011_bb0030","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.011_bb0035","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","article-title":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","volume":"12","author":"Mori","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0040","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.184.6.2271","article-title":"Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice","volume":"184","author":"Wolf","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.182.4.915","article-title":"Successful T cell priming in B cell-deficient mice","volume":"182","author":"Epstein","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/310244a0","article-title":"Autoimmune human T lymphocytes specific for acetylcholine receptor","volume":"310","author":"Hohlfeld","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.011_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0896-8411(91)90013-3","article-title":"T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity","volume":"4","author":"Berrih-Aknin","year":"1991","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0022-510X(82)90033-8","article-title":"T-lymphocytes in experimental autoimmune myasthenia gravis. Isolation of T-helper cell lines","volume":"57","author":"Hohlfeld","year":"1982","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.40.4.581","article-title":"Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report","volume":"40","author":"Nath","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0070","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.52.3.484","article-title":"Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells","volume":"52","author":"Wang","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0075","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.4049\/jimmunol.152.6.3152","article-title":"Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis","volume":"152","author":"Kaul","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0080","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.34.1.66","article-title":"Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis","volume":"34","author":"Berrih","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0090","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0095","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM198111263052203","article-title":"Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes","volume":"305","author":"Newsom-Davis","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4049\/jimmunol.137.4.1221","article-title":"Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes","volume":"137","author":"Lisak","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00915728","article-title":"Invitro antiacetylcholine receptor antibody-synthesis by myasthenia-gravis patient lymphocytes\u2014correlations with thymic histology and thymic epithelial\u2013cell interactions","volume":"7","author":"Safar","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0110","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4049\/jimmunol.136.3.887","article-title":"Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis","volume":"136","author":"Fujii","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1034\/j.1600-0404.2001.00209.x","article-title":"Analysis of immunoglobulin secretion by lymph organs with myasthenia gravis","volume":"103","author":"Yoshikawa","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2013.03.011_bb0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1172\/JCI115843","article-title":"Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis","volume":"90","author":"Schonbeck","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.011_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/1531-8249(199910)46:4<559::AID-ANA3>3.0.CO;2-S","article-title":"Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis [see comments]","volume":"46","author":"Aissaoui","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0896-8411(91)90018-8","article-title":"Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations","volume":"4","author":"Kuks","year":"1991","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0135","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0140","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0150","unstructured":"Weiss JM, Cufi P, Le Panse R, Berrih-Aknin S. The thymus in autoimmune Myasthenia Gravis \u2013 Paradigm for a tertiary lymphoid organ. Rev Neurol in press."},{"key":"10.1016\/j.autrev.2013.03.011_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","volume":"43","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0160","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.4049\/jimmunol.177.11.7868","article-title":"Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia","volume":"177","author":"Le Panse","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.187.4.655","article-title":"B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5","volume":"187","author":"Legler","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21628","article-title":"CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia","volume":"66","author":"Berrih-Aknin","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1074-7613(00)80199-5","article-title":"BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis","volume":"12","author":"Luther","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0180","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1084\/jem.20021761","article-title":"Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase","volume":"197","author":"Drayton","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.imbio.2012.05.006","article-title":"SDF-1\/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients","volume":"218","author":"Weiss","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.autrev.2007.02.016","article-title":"The paradox of CD5-expressing B cells in systemic lupus erythematosus","volume":"7","author":"Youinou","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0195","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.42.5.1081","article-title":"Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals","volume":"42","author":"Yi","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0200","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.42.5.1076","article-title":"Effect of clinical status and treatment on the frequency of CD5+ B cells in patients with myasthenia gravis","volume":"42","author":"Ragheb","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/08916939509001937","article-title":"The CD5+ B cells and myasthenia gravis","volume":"20","author":"Araga","year":"1995","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00878532","article-title":"Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients","volume":"243","author":"Heidenreich","year":"1996","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916939908993860","article-title":"Cell-surface expression of lymphocyte activation markers in myasthenia gravis","volume":"31","author":"Ragheb","year":"1999","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-5728(97)00030-1","article-title":"Expression of CD23 in the germinal center of thymus from myasthenia gravis patients","volume":"76","author":"Murai","year":"1997","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0225","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/WNL.34.4.462","article-title":"Thymic B-cell activation in myasthenia gravis","volume":"34","author":"Levinson","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0230","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2009-10-250423","article-title":"The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress","volume":"116","author":"Auner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0235","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1078\/0171-2985-00204","article-title":"The role of long-lived plasma cells in autoimmunity","volume":"206","author":"Arce","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0240","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/clim.2002.5251","article-title":"ACh receptor protein drives primary and memory autoantibody responses in chimeric human-SCID mice","volume":"104","author":"Yoshikawa","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0245","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein\u2013Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0250","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.22488","article-title":"Intrathymic Epstein\u2013Barr virus infection is not a prominent feature of myasthenia gravis","volume":"70","author":"Kakalacheva","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0255","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ana.22522","article-title":"Lack of evidence for Epstein\u2013Barr virus infection in myasthenia gravis thymus","volume":"70","author":"Meyer","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0260","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1468-1331.2011.03636.x","article-title":"High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis","volume":"19","author":"Csuka","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0265","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: Innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0270","first-page":"59","article-title":"Polyclonal B lymphocyte activation in progressive systemic sclerosis","volume":"29","author":"Famularo","year":"1989","journal-title":"J Clin Lab Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0275","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1212\/WNL.31.9.1198","article-title":"Polyclonal B-cell activity in myasthenia gravis","volume":"31","author":"Levinson","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0280","first-page":"31","article-title":"In vitro T-cell dependent B-cell activity in myasthenia gravis","volume":"61","author":"Limburg","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1054\/jocn.2001.1028","article-title":"Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis","volume":"9","author":"Yoshikawa","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0290","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0295","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.27.6.485","article-title":"Immunological disturbances in myasthenia gravis with a report of Hashimoto's disease developing after thymectomy","volume":"27","author":"Simpson","year":"1964","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.011_bb0300","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0404.1989.tb03881.x","article-title":"Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy","volume":"80","author":"Thorlacius","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2013.03.011_bb0305","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2249.1991.tb05625.x","article-title":"Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families","volume":"83","author":"Guigou","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0310","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0315","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/eji.200939914","article-title":"Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC","volume":"40","author":"Zuckerman","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0320","first-page":"121","article-title":"Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia","volume":"4","author":"Cohen-Kaminsky","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.autrev.2013.03.011_bb0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/imt.11.147","article-title":"Immunotherapeutic implication of IL-6 blockade","volume":"4","author":"Tanaka","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.autrev.2013.03.011_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0169-4758(99)01591-4","article-title":"Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents","volume":"16","author":"Reina-San-Martin","year":"2000","journal-title":"Parasitol Today"},{"key":"10.1016\/j.autrev.2013.03.011_bb0340","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1189\/jlb.0407214","article-title":"Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host?","volume":"82","author":"Montes","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0345","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0350","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of dsRNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0355","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.011_bb0360","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0365","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1006\/jmbi.2001.5296","article-title":"Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes","volume":"315","author":"Karpusas","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0370","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0092-8674(02)00631-1","article-title":"Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands","volume":"108","author":"Liu","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2013.03.011_bb0375","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nsb769","article-title":"Structural basis of BLyS receptor recognition","volume":"9","author":"Oren","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0380","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000082105","article-title":"The biochemistry and biology of BAFF, APRIL and their receptors","volume":"8","author":"Kalled","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0385","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.173.4.2245","article-title":"TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology","volume":"173","author":"Sasaki","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0390","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.4049\/jimmunol.173.4.2331","article-title":"B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation","volume":"173","author":"Shulga-Morskaya","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0395","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: Structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0400","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0405","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/89790","article-title":"Activation and accumulation of B cells in TACI-deficient mice","volume":"2","author":"Yan","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0410","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1074-7613(03)00025-6","article-title":"Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor","volume":"18","author":"Seshasayee","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0415","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/eji.200636623","article-title":"TACI attenuates antibody production costimulated by BAFF-R and CD40","volume":"37","author":"Sakurai","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0420","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ng1600","article-title":"Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans","volume":"37","author":"Salzer","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2013.03.011_bb0425","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.011_bb0430","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0435","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.011_bb0440","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/intimm\/dxh259","article-title":"BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors","volume":"17","author":"Zhang","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0445","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1074-7613(02)00398-9","article-title":"Dendritic cells, BAFF, and APRIL: Innate players in adaptive antibody responses","volume":"17","author":"MacLennan","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0455","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5","article-title":"BAFF is a survival and maturation factor for mouse B cells","volume":"32","author":"Rolink","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0460","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0465","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0470","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1073\/pnas.97.7.3370","article-title":"Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice","volume":"97","author":"Khare","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2013.03.011_bb0475","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0480","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.4049\/jimmunol.179.7.4307","article-title":"A new class of reverse signaling costimulators belongs to the TNF family","volume":"179","author":"Sun","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0485","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/eji.201040591","article-title":"Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses","volume":"41","author":"Bossen","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0490","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0495","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0500","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.4049\/jimmunol.1002176","article-title":"Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF","volume":"185","author":"Ota","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0505","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2006.04.003","article-title":"Regulation of B cell self-tolerance by BAFF","volume":"18","author":"Brink","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0510","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.smim.2006.06.002","article-title":"Impact of the BAFF\/BR3 axis on B cell survival, germinal center maintenance and antibody production","volume":"18","author":"Kalled","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0515","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0520","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2002-10-3123","article-title":"Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF","volume":"101","author":"Craxton","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0525","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/jir.2008.0007","article-title":"BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis","volume":"28","author":"Gandhi","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.autrev.2013.03.011_bb0530","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.011_bb0535","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1074-7613(03)00240-1","article-title":"Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity","volume":"19","author":"Hanada","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0540","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0545","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0550","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1007\/s00415-011-6092-z","article-title":"BAFF serum levels in myasthenia gravis: effects of therapy","volume":"258","author":"Scuderi","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0555","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0560","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/WNL.31.2.220","article-title":"No direct correlation between serum anti-acetylcholine receptor antibody-levels and clinical state of individual patients with myasthenia-gravis","volume":"31","author":"Roses","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0565","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0570","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-3083.2007.01921.x","article-title":"The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis","volume":"65","author":"Thangarajh","year":"2007","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0575","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1052-3359(25)00571-X","article-title":"The thymus and myasthenia gravis","volume":"11","author":"Ragheb","year":"2001","journal-title":"Chest Surg Clin N Am"},{"key":"10.1016\/j.autrev.2013.03.011_bb0580","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2008.05.020","article-title":"Reflections on the \u201cintrathymic pathogenesis\u201d of myasthenia gravis","volume":"201","author":"Hohlfeld","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0585","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.410390414","article-title":"Upregulation of Bcl-2 protein in the myasthenic thymus","volume":"39","author":"Onodera","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0590","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/eji.1830270402","article-title":"Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis","volume":"27","author":"Shiono","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0595","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","article-title":"The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis","volume":"178","author":"Thangarajh","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0600","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0605","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-081232","article-title":"BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells","volume":"111","author":"Badr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0610","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2010.02.013","article-title":"Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia","volume":"221","author":"Shiao","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0615","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1006\/bbrc.1999.0308","article-title":"Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla","volume":"257","author":"Heino","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0620","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0165-2478(01)00314-5","article-title":"Expression of AIRE gene in peripheral monocyte\/dendritic cell lineage","volume":"80","author":"Kogawa","year":"2002","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2013.03.011_bb0625","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.autrev.2005.09.001","article-title":"Disruption of immunological tolerance: role of AIRE gene in autoimmunity","volume":"5","author":"Rizzi","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0630","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/eji.200535240","article-title":"Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator","volume":"36","author":"Ramsey","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0635","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2006-04-019679","article-title":"Aire-deficient mice develop hematopoetic irregularities and marginal zone B-cell lymphoma","volume":"108","author":"Hassler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0640","doi-asserted-by":"crossref","first-page":"18466","DOI":"10.1073\/pnas.0808205105","article-title":"AIRE regulates T-cell-independent B-cell responses through BAFF","volume":"105","author":"Lindh","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2013.03.011_bb0645","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaut.2010.09.007","article-title":"The susceptibility of Aire(\u2212\/\u2212) mice to experimental myasthenia gravis involves alterations in regulatory T cells","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.011_bb0650","series-title":"Handbook of myasthenia gravis and myasthenic syndromes","first-page":"239","article-title":"The immunopathogenesis of acquired (autoimmune) myasthenia gravis","author":"Ragheb","year":"1994"},{"key":"10.1016\/j.autrev.2013.03.011_bb0655","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.1998.tb10931.x","article-title":"Immune regulation and myasthenia gravis","volume":"841","author":"Ragheb","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0660","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0665","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"Diaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0670","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence","volume":"41","author":"Narvaez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0675","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10067-011-1714-5","article-title":"Rituximab in the treatment of severe lupus myelopathy","volume":"30","author":"Ye","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0680","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12016-010-8205-3","article-title":"Rituximab therapy in lupus nephritis: current clinical evidence","volume":"40","author":"Ramos-Casals","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0685","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0690","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.3899\/jrheum.110444","article-title":"Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial","volume":"38","author":"Haraoui","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0695","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2011-200370","article-title":"Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?","volume":"71","author":"Boumans","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.03.011_bb0700","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jbspin.2011.05.002","article-title":"Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure","volume":"79","author":"Solau-Gervais","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2013.03.011_bb0705","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2011.79","article-title":"Rheumatoid arthritis: When should we use rituximab to treat RA?","volume":"7","author":"Yazici","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0710","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0715","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.03.011_bb0720","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14712598.2011.605352","article-title":"Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?","volume":"11","author":"Meiners","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2013.03.011_bb0725","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2249.2011.04460.x","article-title":"Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjogren's syndrome: clinical implications and effects of B cell-targeted therapies","volume":"167","author":"Vossenkamper","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0730","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","article-title":"Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome","volume":"28","author":"Pranzatelli","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0735","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0740","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0745","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0750","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0755","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.011_bb0760","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis\u2013experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2013.03.011_bb0765","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.011_bb0770","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2013.03.011_bb0775","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CND.0b013e3181df2b3e","article-title":"Rituximab in the treatment of MuSK antibody-positive myasthenia gravis","volume":"12","author":"Stein","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2013.03.011_bb0780","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0785","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0790","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2013.03.011_bb0795","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.011_bb0800","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0805","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.011_bb0810","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.03.011_bb0815","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0820","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cyto.2010.12.004","article-title":"Chemokine\/cytokine profiling after rituximab: reciprocal expression of BCA-1\/CXCL13 and BAFF in childhood OMS","volume":"53","author":"Pranzatelli","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2013.03.011_bb0825","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2013.03.011_bb0830","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0835","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2013.03.011_bb0840","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2013.03.011_bb0845","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1517\/14796694.1.2.161","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"1","author":"Richardson","year":"2005","journal-title":"Future Oncol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0850","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2013.03.011_bb0855","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard.2010.133256","article-title":"Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma","volume":"70","author":"Frohlich","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.03.011_bb0860","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0865","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0870","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.011_bb0875","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2007-04-088088","article-title":"Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2013.03.011_bb0880","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/toxsci\/kfn105","article-title":"Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept","volume":"105","author":"Carbonatto","year":"2008","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0885","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0890","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.03.011_bb0895","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2013.03.011_bb0900","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(01)00130-3","article-title":"Regulation of the T-independent humoral response by TACI","volume":"14","author":"von Bulow","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2013.03.011_bb0905","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458511398887","article-title":"Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid","volume":"17","author":"Ragheb","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2013.03.011_bb0910","first-page":"99","article-title":"Treatment of myasthenia gravis: long-term administration of corticosteroids with remarks on thymectomy","volume":"17","author":"Johns","year":"1977","journal-title":"Adv Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0915","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0920","first-page":"221","article-title":"Myasthenia gravis","volume":"12","author":"Acsadi","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.autrev.2013.03.011_bb0925","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: Guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0930","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0935","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1212\/01.wnl.0000259335.05741.5f","article-title":"IVIG in myasthenia gravis: getting enough \u201cbang for the buck\u201d","volume":"68","author":"Meriggioli","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.011_bb0940","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1196\/annals.1405.038","article-title":"IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies","volume":"1132","author":"Zinman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.011_bb0945","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.011_bb0950","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10875-007-9082-2","article-title":"BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer","volume":"27","author":"Le Pottier","year":"2007","journal-title":"J Clin Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T02:06:33Z","timestamp":1745978793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":190,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1568997213000384"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.011","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}